She Lived to 117 - and Her Body Still Aged. That May Be the Most Important Part.

She Was 117. Her Biology Knew It.

There is a tendency in longevity medicine to assume that anyone who reaches an extraordinary age must somehow have remained biologically young. This study tells a more complicated story, and a much more interesting one.

Researchers performed one of the most detailed biological examinations ever conducted on a supercentenarian, a woman who lived to 117 years and 168 days. She was born in San Francisco in 1907 to Spanish parents and moved to Spain at age eight, where she spent most of her life. By examining her genome, blood-cell gene expression, proteins, metabolites, gut microbiome and epigenome, the investigators were able to compare several different dimensions of aging rather than relying on a single laboratory marker.

The picture that emerged was anything but uniformly youthful. Some aspects of her biology looked every bit as old as 117, while others appeared remarkably well preserved. That coexistence may be more informative than another attempt to identify a single molecule, pathway or supplement capable of explaining extreme longevity.

Her Telomeres Were Not Young

Telomeres are often discussed as though they provide something close to a biological longevity score. They shorten with repeated cell division and aging, and the commercial longevity world has understandably embraced the appealing idea that longer telomeres must therefore mean a younger and healthier body.

This woman complicates that interpretation considerably. Her average telomere length was barely 8 kilobases, the shortest among the healthy volunteers used for comparison in this portion of the study, and roughly 40% of her telomeres fell below the investigators' 20th percentile threshold for short telomeres.

Those findings are entirely consistent with advanced biological age, yet she had reached 117 without the major neurodegenerative, metabolic or cardiovascular diseases we might expect to accompany such profound cellular aging. The researchers raise the possibility that telomere shortening in someone like this may function partly as a record of accumulated cellular history rather than as a simple prediction of who will or will not develop disease.

That distinction matters. A biomarker can accurately reflect one aspect of aging without being capable of predicting the entire biological future of the person attached to it. This is one reason we are cautious about reducing longevity to any single laboratory value.

She Carried Age-Related Mutations Too

The same pattern appeared in her blood. Researchers identified clonal hematopoiesis of indeterminate potential, commonly called CHIP, including mutations involving SF3B1 and TET2. CHIP becomes increasingly common with age and is associated with increased risk of blood cancers and cardiovascular disease.

Despite carrying those mutations, she apparently never developed either of those outcomes. That does not make CHIP harmless, nor does it argue against monitoring it when it is found. What it illustrates is the difference between increased risk and biological destiny.

A mutation can increase the probability of disease without being sufficient to produce it. Immune surveillance, inflammatory signaling, metabolic health, additional genetic changes and countless interactions among those systems may determine whether a risk eventually becomes a diagnosis.

One of the more intriguing possibilities raised by this study is that extraordinary longevity may depend less on completely avoiding molecular damage than on remaining unusually capable of containing its consequences.

Her Metabolic Health Was Remarkable

The cardiovascular and metabolic findings may provide some of the strongest clues in the entire paper. The researchers described her lipid metabolism as exceptionally efficient, with extremely low VLDL cholesterol and triglycerides, high HDL cholesterol and a lipoprotein pattern suggesting effective lipid transport and processing.

It would be easy to reduce that observation to another claim that high HDL is protective or somehow explains longevity. Cardiovascular biology is far more complicated than that, and we would not interpret the finding that way.

What is more interesting is the larger metabolic environment in which those lipids existed. GlycA and GlycB, two integrated markers of systemic inflammatory activity, were very low. The combination of efficient lipid handling and remarkably little chronic inflammatory burden paints a more meaningful picture than any single cholesterol number could provide.

That is also much closer to how we think about preventive cardiology. Risk develops within a biological system. Lipoproteins, inflammation, glucose metabolism, vascular health, genetics, blood pressure, body composition and lifestyle interact continuously, and their combined effect is far more important than the mythology surrounding one supposedly good or bad number.

Her Immune System Had Aged, but Something Was Different

Her immune system offered another example of aging without the expected degree of disease. She had fewer naive immune cells, more senescent T cells and an expanded population of age-associated B cells. None of those findings would lead anyone to describe her immune system as young.

What was unusual was the relatively low inflammatory burden accompanying those changes. Gene-expression studies also identified features resembling younger individuals, including an autophagy-related profile that clustered more closely with younger controls than might be expected in someone of her age.

This is particularly interesting in the context of inflammaging, the chronic low-grade inflammatory state increasingly associated with cardiovascular disease, metabolic dysfunction, frailty, neurodegeneration and other conditions of aging. Successful aging may not require preserving a youthful immune system indefinitely. It may depend partly on preventing an aging immune system from spending decades generating damaging levels of chronic inflammation.

And Then There Is the Yogurt

The microbiome findings are probably the part of this study most likely to take on a life of their own online. Her gut microbiome was unusually diverse and contained strikingly high levels of Bifidobacterium, a bacterial genus that typically declines with age but has been found at relatively high levels in centenarians and supercentenarians.

The researchers also reported that she consumed approximately three yogurts a day. Those yogurts contained Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus, organisms that may help create an intestinal environment favorable to Bifidobacterium. Her broader dietary pattern was Mediterranean, which adds another plausible influence on the gut ecosystem.

None of this demonstrates that yogurt was responsible for her longevity. The investigators could not establish that her yogurt intake caused the microbiome they observed, and there are many other possible explanations. Genetics, lifelong diet, immune function, geography, environment and the simple fact that she represented an extremely unusual biological phenotype could all have played a role.

The reasonable conclusion is not that three yogurts a day is a longevity intervention. It is that the gut microbiome, metabolism and inflammatory regulation appear to remain closely connected even at the farthest extremes of human lifespan.

Her Epigenetic Age May Be the Most Fascinating Finding

The researchers also examined DNA methylation, one of the best-studied forms of epigenetic regulation and the basis for several biological aging clocks. Unlike chronological age, these clocks attempt to estimate aspects of biological aging by examining predictable changes in DNA methylation patterns.

Across multiple tissues and several different clocks, she consistently appeared biologically younger than her chronological age. A separate analysis based on ribosomal-DNA methylation estimated an age roughly 23 years below her actual chronological age, and the investigators calculated a substantial slowing of her methylation-aging trajectory.

This deserves attention, but it also deserves careful language. An epigenetic clock is a statistical model, not a literal measurement of how old every organ in the body is. A 117-year-old receiving a methylation-age estimate in the 90s does not mean that her brain, heart, kidneys, muscles and immune system suddenly functioned like those of an average person in their 90s.

The stronger interpretation is also the more interesting one: her epigenetic biology was unusually youthful for someone who had reached such an extraordinary chronological age. Several different measures pointed in the same direction, suggesting that chronological age and at least some components of biological aging can become partially uncoupled.

This Is Not a Longevity Prescription

There is one limitation that should remain front and center throughout any discussion of this study: it examined one person. She was, by definition, an extreme biological outlier, and researchers identified unusual genetic variants involving cardiovascular protection, immune function, brain health and mitochondrial biology, including rare combinations not seen in the comparison populations they examined.

We cannot separate the contribution of those inherited advantages from the effects of diet, movement, environment, social circumstances, medical history or simple biological chance. The authors acknowledge this directly and emphasize that larger cohorts and prospective research will be necessary before any of these observations can reasonably be translated into anti-aging interventions.

For that reason, this paper should not be read as an instruction to lengthen telomeres, take a particular probiotic, eat three yogurts a day or chase a lower epigenetic-age score. Each of those conclusions would move far beyond what the study actually demonstrated.

What the paper gives us instead is a more useful framework for thinking about aging.

Maybe the Goal Isn't to Stop Aging

Much of modern anti-aging culture is built around the assumption that every measurable sign of aging needs to be pushed backward. Telomeres should be longer, biological clocks should be younger, hormone levels should resemble an earlier decade, and laboratory markers should somehow remain permanently fixed in youth.

This woman suggests that healthy longevity may be considerably more complicated. Her telomeres shortened, her blood-forming cells accumulated mutations and her immune system underwent profound age-related changes. At the same time, her metabolism, inflammatory regulation, mitochondrial activity, genomic stability and several aspects of her epigenetic biology remained unusually resilient.

The distinction is important because a body does not have to remain biologically young in every measurable way to remain remarkably functional. What may matter more is preserving enough physiological capacity that aging does not inevitably become diabetes, cardiovascular disease, frailty, dementia, cancer or loss of independence.

That is a much more realistic goal for preventive longevity medicine. We cannot promise to stop biological aging, and we should be skeptical of anyone who says we can. We can, however, work to preserve muscle and bone, maintain metabolic and cardiovascular health, protect cognitive function, manage chronic inflammation, maintain nutritional adequacy and identify disease risk while there is still time to change its trajectory.

This woman reached 117 with a body that had unquestionably aged. The remarkable part was not that aging failed to occur. It was how successfully so much of her physiology continued to function despite it.

That may be one of the most useful longevity lessons we have.

For more evidence-based discussion of aging, prevention and healthspan, visit the HormoneSynergy Longevity Medicine Resource Library or learn more about our Optimal Aging Assessment.

Frequently Asked Questions

Who was studied in this longevity research?

The researchers studied a woman who was the world's oldest verified living person during part of the study period and who ultimately lived to 117 years and 168 days. She was born in San Francisco to Spanish parents and moved to Spain at age eight. Researchers examined multiple layers of her biology, including her genome, blood-cell gene expression, proteins, metabolites, gut microbiome and epigenome.

Did she have the biological markers of a younger person?

Some aspects of her biology appeared unusually youthful, while others clearly reflected extreme age. She had very short telomeres, clonal hematopoiesis and aged immune-cell populations, but her metabolic, inflammatory, microbiome and epigenetic profiles contained several unusually favorable features. The study is valuable precisely because both patterns existed in the same individual.

Was her biological age really 23 years younger?

One ribosomal-DNA methylation clock estimated her biological age approximately 23 years below her chronological age, and several other epigenetic clocks also produced younger estimates. These tests measure statistical patterns of DNA methylation and should not be interpreted as literal measurements of the age of every organ or cell in the body.

Did eating yogurt help her live to 117?

The study cannot establish that. She reportedly consumed around three yogurts a day and had unusually high levels of Bifidobacterium in her gut microbiome, but the researchers could not determine whether yogurt caused that microbial pattern or contributed directly to her longevity. Her genetics, Mediterranean dietary pattern, immune function, environment and other lifelong factors may all have contributed.

Does this study prove that telomere length does not matter?

No. Telomere shortening remains an important feature of cellular aging. What this case demonstrates is that extremely short telomeres can coexist with exceptional longevity and relatively good health, which is one reason telomere length should not be treated as a standalone measure of an individual's healthspan or expected lifespan.

What is the most important finding from the study?

The larger message is that aging and age-related disease may not be inseparable. This woman accumulated substantial molecular signs of aging while maintaining unusually resilient metabolic, inflammatory, genetic and epigenetic characteristics. The researchers propose that under certain circumstances, biological aging and the diseases commonly associated with it can become partially decoupled.

Editorial Transparency

Published August 2026. This article discusses an observational multiomics study of a single supercentenarian published in Cell Reports Medicine. Because the research examined one exceptional individual, it cannot establish that any diet, supplement, microbiome pattern, genetic variant, epigenetic measurement or other intervention causes extreme longevity. HormoneSynergy has no financial relationship with the study authors or publisher. Our interpretation focuses on what this research may teach us about biological resilience, healthspan and preventive longevity medicine.

Source

Santos-Pujol E, Noguera-Castells A, Casado-Pelaez M, et al. The multiomics blueprint of the individual with the most extreme lifespan. Cell Reports Medicine. 2025;6:102368. View the study.